FDA Advisers Recommend Updated Boosters Targeting Forms of Omicron

Posted by Argentum on June 30, 2022

Instead of keeping with COVID-19 vaccine boosters that target the original strain of SARS-CoV-2, an FDA advisory panel said this week that it favors reformulating the doses to also work against newer Omicron subtypes, reports the New York Times.

Read More

Topics: Vaccine

COVID-19 Vaccinations Approved for Children as Young as 6 Months Old

Posted by Argentum on June 22, 2022

To the relief of many parents and caregivers, panels for the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have determined that the known and potential benefits of vaccinating children 6 months of age and older outweigh the known and potential risks in the pediatric populations authorized for use for use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine. Vaccinations began this week.

Read More

Topics: Vaccine

Moderna asks FDA to authorize second booster for adults

Posted by Argentum on March 18, 2022

Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its Covid-19 vaccine as a booster dose for all adults.

Read More

Topics: Vaccine

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose for Older Adults

Posted by Argentum on March 16, 2022

Pfizer Inc. and BioNTech SE today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose for adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The submission is based on two real-world data sets from Israel analyzed at a time when the Omicron variant was widely circulating. These data showed evidence that an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and severe illness.

Read More

Topics: Vaccine

Moderna Vaccine Gets Full FDA Approval

Posted by Argentum on January 31, 2022

The U.S. Food and Drug Administration has approved the Moderna vaccine, making it the second COVID-19 vaccine to go from emergency use authorization (EUA) to full approval. With this approval, the company will begin to market the vaccine under the name Spikevax. The approval means the vaccine has met FDA standards for “safety, effectiveness, and manufacturing quality,” according to the FDA.

Read More

Topics: Vaccine

CDC Recommends mRNA Vaccines Over Johnson & Johnson

Posted by Argentum on December 17, 2021

The CDC yesterday announced that it is preferable to get an mRNA vaccine—such as Pfizer or Moderna in a two-shot series—over the Johnson & Johnson one-shot vaccine.  

Read More

Topics: Vaccine

Boosters Recommended for Ages 16-17; Preventive Use of Monoclonal Antibodies Gets EUA

Posted by Argentum on December 9, 2021

CDC director Dr. Rochelle Walensky today announced that the CDC recommends and encourages booster shots for ages 16 and 17, as well as reinforcing the previous announcement that those older than 18 get the booster.  

Read More

Topics: Vaccine

CDC Says 18+ ‘Should’ Get Booster

Posted by Argentum on December 1, 2021

The CDC made a change to its recommendations, saying “Everyone ages 18 and older should get a booster shot.” Previously, the CDC had said everyone “may” get a booster. This stronger recommendation comes in the wake of the emergence of the Omicron variant and the prospect of winter holidays, travel, and close quarters.  

Read More

Topics: Vaccine

Omicron Variant: Resources to Keep Up with the Changing Picture

Posted by Argentum on November 29, 2021

While the World Health Organization has classified a new variant of the coronavirus, Omicron, as a “variant of concern,” as of Nov. 26, no cases have been reported in the United States.

Read More

Topics: Vaccine

Boosters for All Move Goes to CDC Committee

Posted by Argentum on November 19, 2021

The U.S. Food and Drug Administration has authorized a single booster dose for all individuals 18 and older who have had their primary vaccinations. The booster would be given six months after the primary series with Moderna or Pfizer, and two months after Johnson & Johnson.

Read More

Topics: Vaccine

Subscribe to Instant Email Updates

See More COVID-19 Announcements

Read more announcements related to COVID-19 on our Coronavirus Blog and access more information on:

SEE BLOG

Stay Updated on COVID-19

Find all of our latest updates on developments related to COVID-19 on our Coronavirus Toolkit.

SEE TOOLKIT